Literature DB >> 20010914

Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

D Proudnikov1, T Kroslak, J C Sipe, M Randesi, D Li, S Hamon, A Ho, J Ott, M J Kreek.   

Abstract

Alterations in expression of a cannabinoid receptor (CNR1, CB1), and of fatty acid amide hydrolase (FAAH) that degrades endogenous ligands of CB1, may contribute to the development of addiction. The 385C>A in the FAAH gene and six polymorphisms of CNR1 were genotyped in former heroin addicts and control subjects (247 Caucasians, 161 Hispanics, 179 African Americans and 19 Asians). In Caucasians, long repeats (>or=14) of 18087-18131(TAA)(8-17) were associated with heroin addiction (P=0.0102). Across three ethnicities combined, a highly significant association of long repeats with heroin addiction was found (z=3.322, P=0.0009). Point-wise significant associations of allele 1359A (P=0.006) and genotype 1359AA (P=0.034) with protection from heroin addiction were found in Caucasians. Also in Caucasians, the genotype pattern, 1359G>A and -6274A>T, was significantly associated with heroin addiction experiment wise (P=0.0244). No association of FAAH 385C>A with heroin addiction was found in any group studied.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20010914      PMCID: PMC3810151          DOI: 10.1038/tpj.2009.59

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  44 in total

1.  No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population.

Authors:  T Li; X Liu; Z H Zhu; J Zhao; X Hu; D M Ball; P C Sham; D A Collier
Journal:  Mol Psychiatry       Date:  2000-03       Impact factor: 15.992

2.  The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction.

Authors:  Jonathan M Flanagan; Alexandra L Gerber; Jean Lud Cadet; Ernest Beutler; Jack C Sipe
Journal:  Hum Genet       Date:  2006-09-14       Impact factor: 4.132

3.  Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1.

Authors:  S Leroy; N Griffon; M C Bourdel; J P Olié; M F Poirier; M O Krebs
Journal:  Am J Med Genet       Date:  2001-12-08

4.  Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats.

Authors:  Taco J De Vries; Judith R Homberg; Rob Binnekade; Halfdan Raasø; Anton N M Schoffelmeer
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

5.  (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population.

Authors:  N Ballon; S Leroy; C Roy; M C Bourdel; A Charles-Nicolas; M O Krebs; M F Poirier
Journal:  Pharmacogenomics J       Date:  2006 Mar-Apr       Impact factor: 3.550

6.  The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users.

Authors:  D. Heller; U. Schneider; J. Seifert; K. F. Cimander; M. Stuhrmann
Journal:  Addict Biol       Date:  2001-04       Impact factor: 4.280

7.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats.

Authors:  M Navarro; J Chowen; M Rocío A Carrera; I del Arco; M A Villanúa; Y Martin; A J Roberts; G F Koob; F R de Fonseca
Journal:  Neuroreport       Date:  1998-10-26       Impact factor: 1.837

9.  No association of CNR1 gene variations with susceptibility to schizophrenia.

Authors:  Jürgen Seifert; Sebastian Ossege; Hinderk M Emrich; Udo Schneider; Manfred Stuhrmann
Journal:  Neurosci Lett       Date:  2007-08-10       Impact factor: 3.046

10.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  18 in total

Review 1.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

2.  Genetic variation in FAAH is associated with cannabis use disorders in a young adult sample of Mexican Americans.

Authors:  Whitney E Melroy-Greif; Kirk C Wilhelmsen; Cindy L Ehlers
Journal:  Drug Alcohol Depend       Date:  2016-06-25       Impact factor: 4.492

3.  Risky alcohol consumption in young people is associated with the fatty acid amide hydrolase gene polymorphism C385A and affective rating of drug pictures.

Authors:  Kora-Mareen Bühler; Evelio Huertas; Víctor Echeverry-Alzate; Elena Giné; Eduardo Moltó; Lluis Montoliu; Jose Antonio López-Moreno
Journal:  Mol Genet Genomics       Date:  2014-01-10       Impact factor: 3.291

4.  Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.

Authors:  Oscar Sasso; Rosalia Bertorelli; Tiziano Bandiera; Rita Scarpelli; Giampiero Colombano; Andrea Armirotti; Guillermo Moreno-Sanz; Angelo Reggiani; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2012-03-07       Impact factor: 7.658

Review 5.  Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

Authors:  C J Hillard; K M Weinlander; K L Stuhr
Journal:  Neuroscience       Date:  2011-11-17       Impact factor: 3.590

6.  Involvement of Endocannabinoids in Alcohol "Binge" Drinking: Studies of Mice with Human Fatty Acid Amide Hydrolase Genetic Variation and After CB1 Receptor Antagonists.

Authors:  Yan Zhou; Ted Huang; Francis Lee; Mary Jeanne Kreek
Journal:  Alcohol Clin Exp Res       Date:  2016-02-09       Impact factor: 3.455

Review 7.  Pharmacogenetics of new analgesics.

Authors:  Jörn Lötsch; Gerd Geisslinger
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 8.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

9.  Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history.

Authors:  Dmitri Proudnikov; Matthew Randesi; Orna Levran; Vadim Yuferov; Howard Crystal; Ann Ho; Jurg Ott; Mary J Kreek
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

10.  Lack of association of DRD3 and CNR1 polymorphisms with premenstrual dysphoric disorders.

Authors:  Mesut Yıldız; Mehmet Vural; Mehmet Emin Erdal; Özlem İzci Ay; Şenay Görücü Yılmaz; İbrahim Fatih Karababa; Salih Selek
Journal:  Iran J Reprod Med       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.